转移性分化型甲状腺癌的DNA甲基化动态及其预后意义
这项多中心回顾性研究在五所大学医院手术的分化型甲状腺癌患者中分析DNA甲基化,发现从原发瘤到远处转移以低甲基化为主的改变进行性增加,乳头状与滤泡状癌动态不同,并在原发瘤中识别和验证了一个可区分非转移与转移患者的156-CpG特征。
要点
- DNA甲基化改变以低甲基化为主,从原发瘤到远处转移进行性增加。
- 非转移性原发乳头状癌低甲基化CpG多于高甲基化,与滤泡状癌相反。
- 原发瘤156-CpG特征或有助于识别远处转移高危患者。
核心结论
- 乳头状和滤泡状甲状腺癌转移进展中DNA甲基化改变进行性增加,以低甲基化为主,提示线性模型,但两种组织学类型的DNA甲基化动态不同。
- 原发瘤中156-CpG特征分析可能有助于识别远处转移高危的分化型甲状腺癌患者,促进更个性化治疗。
研究设计与样本
- 多中心回顾性研究,纳入在五所大学医院接受手术的分化型甲状腺癌患者。
- 发现系列共97份样本:15份正常组织、30份非转移原发灶、35份转移原发灶和17份配对转移灶(淋巴结和远处转移)。
- 结果在独立系列中验证,包括17例非转移和13例转移患者。
- 采用受试者工作特征曲线分析评估所识别的预后CpG特征。
主要发现
- 从原发瘤到远处转移,DNA甲基化改变(多为低甲基化)在乳头状和滤泡状甲状腺癌中均进行性增加。
- 与正常组织相比,非转移原发乳头状癌的低甲基化CpG多于高甲基化CpG,而非转移原发滤泡状癌则相反。
- 转移性肿瘤(转移性乳头状癌和转移性滤泡状癌)均以低甲基化CpG为主。
- 差异甲基化CpG重叠率在非转移乳头状癌与非转移滤泡状癌之间较低(14%的非转移乳头状癌差异甲基化CpG见于非转移滤泡状癌),而在转移性乳头状癌与转移性滤泡状癌之间显著更高(60%的转移性乳头状癌差异甲基化CpG见于转移性滤泡状癌)。
- 转移原发瘤中许多新出现的差异甲基化CpG(83%来自转移性乳头状癌、40%来自转移性滤泡状癌)见于远处转移(包括异时性远处转移),支持远处转移起源于原发瘤主要亚克隆的假说。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Distant metastases (DM) are the leading cause of thyroid cancer-related death in patients with differentiated thyroid cancer (DTC). Despite significant progress in understanding DNA methylation in DTC, the methylation landscape of metastatic primary tumors and DM remains unclear. Our primary objective was to investigate DNA methylation dynamics during DTC progression, with a secondary goal of assessing potential clinical implications. Materials and Methods: We conducted a multicenter retrospective study in patients with DTC who underwent surgery at five university hospitals. We profiled DNA methylation in a discovery series of 97 samples (15 normal tissues, 30 non-metastatic [non-mDTC], and 35 metastatic [mDTC] primary DTC, and 17 paired metastases [lymph nodes and DM]). Results were validated in an independent series of 17 non-mDTC and 13 mDTC. We used receiver operating characteristic curve analysis to evaluate the identified prognostic CpG-signature. Results: DNA methylation alterations, mostly hypomethylation, increased progressively from primary tumors to DM, both in papillary (PTC) and follicular (FTC) thyroid carcinomas. Compared with normal tissue, non-metastatic primary PTC (non-mPTC) exhibited more hypomethylated than hypermethylated CpGs in contrast to non-metastatic primary FTC (non-mFTC). However, metastatic tumors, both mPTC and mFTC, predominantly exhibited hypomethylated CpGs. The overlap of differentially methylated CpGs (DMe-CpGs) was low between non-mPTC and non-mFTC (14% non-mPTC DMe-CpGs present in non-mFTC) but significantly higher between mPTC and mFTC (60% mPTC DMe-CpGs present in mFTC), underscoring the convergence of epigenetic changes during metastatic progression. The presence of many de novo DMe-CpGs from metastatic primary tumors (83% from mPTC and 40% from mFTC) in DM, including metachronous DM, supports the hypothesis that DM originates from a major subclone of the primary tumor. We identified and validated a 156-CpG signature in primary tumors capable of distinguishing between non-mDTC and mDTC, offering potential prognostic value for DM development regardless of histology. Conclusions: These results show a progressive increase in DNA methylation alterations, mainly hypomethylation, during PTC and FTC metastatic progression, suggesting a linear model, though the DNA methylation dynamics differs between the two histological types. The analysis of the 156-CpG signature in primary tumors may help identify patients with DTC at high risk for DM, enhancing a more personalized treatment.
引用
- Rodríguez-Lloveras H, Zafon C, Iglesias C, et al. DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer. Thyroid. 2025. PMID: 40045915. doi:10.1089/thy.2024.0303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。